Collectively, research to date has shown that Ruminococcaceae is greater in patients who respond to anti-PD-1 or anti-CTLA-4 treatments across a variety of cancer types and may have potential as a therapeutic adjuvant to ICI treatments. This evidence concerns the gene PDCD1 and cancer.